1. Introduction

Reproductive health biotechnology refers to the application of modern biological, medical, and genetic technologies to human reproduction, fertility treatment, pregnancy management, embryo development, genetic screening, and reproductive healthcare.

In Morocco, reproductive health biotechnology is regulated through a combination of healthcare legislation, assisted-reproduction rules, medical ethics, family law, constitutional protections, and personal-data legislation.

The principal legal concern is balancing three interests:

Reproductive autonomy: Protecting individuals' interests in making decisions about reproduction and fertility treatment.

Medical and scientific safety: Ensuring that reproductive technologies are performed by qualified professionals under appropriate clinical standards.

Family and social protection: Preserving legally recognized parentage, marriage-related requirements, human dignity, and the interests of children.

An important feature of the Moroccan system is that medically assisted reproduction is not treated simply as an ordinary commercial medical service. It is subject to specific statutory restrictions because it can affect filiation, inheritance, family relationships, and the legal status of children.

2. Principal legislation governing reproductive biotechnology

A. Law No. 47-14 of 2019 on Medically Assisted Reproduction

Principal legislation

The most important legislation is Law No. 47-14, promulgated by Dahir No. 1-19-50 of 11 March 2019 and published in the Official Gazette on 4 April 2019.

It establishes a specific legal framework for medically assisted reproduction (MAR), commonly known in French as assistance médicale à la procréation (AMP).

Article 1 identifies two principal purposes:

Treating medically diagnosed pathological infertility.

Preventing the transmission of serious diseases to an unborn child or a spouse where the disease affects reproduction.

Article 2 covers techniques including:

In-vitro fertilisation (IVF).

Intrauterine insemination.

Embryo transfer.

Preservation of reproductive tissues.

Preservation of embryos and gametes.

Other clinically and biologically assisted reproductive techniques.

This law establishes that reproductive biotechnology must operate within statutory medical, ethical and legal boundaries.

Ma Loi+1

B. Law No. 131-13 on the Practice of Medicine

Law No. 131-13, promulgated in 2015, regulates medical practice in Morocco.

It is relevant to reproductive biotechnology because fertility treatment must be undertaken by appropriately qualified and authorised medical professionals.

Its regulatory importance includes:

Professional qualifications and registration.

Compliance with medical practice requirements.

Professional responsibility for clinical decisions.

Medical standards and patient safety.

Accountability for negligent or unauthorised medical practice.

The Ministry of Health identifies this law within its official collection of legislation governing medical professions.

sante.gov.ma+1

C. Law No. 09-08 on Personal Data Protection

Law No. 09-08 of 18 February 2009 is particularly important because reproductive biotechnology involves highly confidential information.

Such information may include:

DNA profiles.

Genetic abnormalities.

Infertility diagnoses.

Embryonic genetic information.

Reproductive medical histories.

Pregnancy and fertility-treatment records.

Article 1 expressly includes health and genetic information within sensitive personal data.

Articles 3 and 4 establish requirements concerning lawful processing, specified purposes, data quality and consent.

Articles 23–26 address security, authorised access and professional confidentiality.

The National Commission for the Control of Personal Data Protection (CNDP) supervises compliance with this legislation.

BDJ+2

D. Moroccan Family Code (Moudawana), Law No. 70-03

The Family Code is important because reproductive technologies can create questions about legal parentage, marriage, inheritance and the identity of children.

Articles 150–156 address the establishment and proof of paternity.

Article 152 identifies three principal grounds for establishing paternity:

The marital bed.

Acknowledgment.

Sexual relations by mistake.

Article 153 deals with the evidentiary significance of the marital relationship and permits judicially ordered conclusive expertise in specified circumstances.

These provisions must be read together with Law No. 47-14, which requires assisted reproduction to use the reproductive cells of the married couple themselves.

ويكي مصدر+2

3. Eligibility requirements for reproductive biotechnology services

One of the most significant features of Moroccan law is the restriction on who may access legally regulated medically assisted reproduction.

Under Article 12 of Law No. 47-14, treatment is available only to:

A married woman and man.

Both spouses must be alive.

The treatment must use their own reproductive cells.

Both spouses must submit a written and duly signed request.

A certified copy of their marriage certificate must accompany the application.

This creates a legally restricted framework for accessing assisted reproduction.

Legal implications

The eligibility provisions demonstrate that Moroccan law connects reproductive treatment with legally recognised marriage and biological parentage.

Ma Loi+2

4. Regulation of IVF and artificial insemination

In-vitro fertilisation and artificial insemination are among the principal technologies regulated under Law No. 47-14.

A. In-vitro fertilisation

IVF involves removing an egg from a woman's ovary, fertilising it with sperm in a laboratory and transferring the resulting embryo into the uterus.

In Morocco, IVF must comply with the following conditions:

The couple must satisfy Article 12.

The infertility or relevant medical indication must be established.

The treatment must be conducted in an authorised medical establishment.

The medical practitioner must hold the required approval.

Both spouses must provide informed written consent.

The procedure must comply with recognised medical practices.

B. Artificial insemination

Article 2 recognises intrauterine insemination involving the preparation of the husband's sperm and its introduction into the wife's uterus using appropriate medical devices.

The use of donor sperm is prohibited because the law requires the spouses to use their own gametes.

C. Medical supervision

Articles 14–16 require recognised techniques, compliance with good medical practices and verification of the spouses' identities, eligibility and consent.

Consequently, fertility clinics cannot independently introduce experimental reproductive technologies without satisfying the applicable regulatory requirements.

Ma Loi+2

5. Regulation of reproductive genetic screening

Reproductive genetic screening is an important part of modern reproductive biotechnology.

It can identify genetic abnormalities that may result in serious hereditary diseases.

Moroccan law addresses this issue through the provisions concerning preimplantation genetic diagnosis (PGD).

Articles 19–21 of Law No. 47-14

Article 19 restricts preimplantation diagnosis to identifying incurable diseases included in the prescribed regulatory list, with the objective of protecting the future child.

Only healthy embryos may be transferred under this framework.

Article 20 establishes a limited exception where preimplantation diagnosis is intended to permit therapeutic treatment of an embryo. This is subject to strict statutory conditions and written consent from both spouses.

Article 21 establishes additional medical requirements, including prescription by an authorised practitioner and consultation with genetic specialists.

Legal significance

These provisions distinguish medical genetic screening from genetic selection for non-medical purposes.

For example:

Screening for a serious hereditary disease may be permitted under the statutory conditions.

Selecting embryos for preferred physical characteristics is not an authorised purpose.

Eugenic selection is expressly prohibited.

Reproductive cloning is prohibited.

This framework attempts to ensure that genetic technologies serve legitimate medical objectives rather than commercial or discriminatory reproductive preferences.

Ma Loi+2

6. Prohibition of reproductive cloning, surrogacy and commercialisation

Morocco adopts strict restrictions on certain reproductive biotechnology practices.

A. Reproductive cloning

Article 4 expressly prohibits reproductive cloning.

The prohibition covers practices intended to produce a child genetically identical to another living or deceased person.

B. Surrogacy

Article 5 expressly prohibits gestation for another person (gestation pour autrui).

This means that a woman cannot legally enter into a regulated reproductive arrangement to carry an embryo for another couple and surrender the child to them after birth.

C. Sale and donation of reproductive material

Article 5 prohibits the donation or sale of:

Human sperm.

Human eggs.

Embryos.

Germinal tissues.

The law therefore adopts a biological-parentage model rather than a donor-based reproductive model.

D. Commercial exploitation of embryos

Article 6 prohibits the creation or use of human embryos for commercial or industrial purposes.

Article 7 prohibits research on human embryos and foetuses, as well as creating embryos for research or experimentation.

These provisions establish important limitations on commercial reproductive biotechnology and embryo-related scientific activities.

Ma Loi+2

7. Regulation of embryo and gamete preservation

Cryopreservation is important for patients who need to preserve fertility or embryos for later treatment.

Moroccan law regulates this activity through Articles 22–30 of Law No. 47-14.

A. Embryo preservation

Article 22 permits embryo preservation for the purpose of improving the chances of pregnancy through subsequent embryo transfer.

The spouses decide, in consultation with the practitioner, the number of embryos to preserve.

B. Gamete preservation

Article 23 generally requires gametes collected from the spouses to be used in fertilisation.

It recognises limited preservation arrangements where the spouses' gametes cannot be collected simultaneously.

Article 24 permits individuals undergoing or preparing for treatment that may damage their fertility, or facing premature fertility deterioration, to preserve gametes or germinal tissues for future use.

C. Preservation period

Article 25 establishes a maximum initial preservation period of five years for the material covered by Article 24, renewable where legitimate reasons justify renewal.

Article 26 provides for destruction after the applicable preservation period, following the prescribed notification procedure.

D. Traceability and transport

Articles 27–29 establish requirements concerning records, preservation, quality and traceability.

Article 30 prohibits exporting embryos, gametes and germinal tissues abroad and importing embryos into Morocco. Importation of gametes and germinal tissues is possible only with special administrative authorisation and under the specified conditions.

These rules are intended to prevent unauthorised transfers, loss of biological identity and commercial exploitation.

Ma Loi+2

8. Licensing and regulation of reproductive health biotechnology centres

Moroccan law does not allow any private clinic or laboratory to offer assisted reproductive technologies without the necessary authorisation.

Articles 8–11 of Law No. 47-14 establish the institutional framework.

The principal requirements include:

1. Institutional authorisation

Article 8 requires assisted reproduction to take place in authorised private assisted-reproduction centres or authorised public or private healthcare establishments.

2. Professional authorisation

Article 9 requires clinical and biological procedures to be performed by appropriately qualified practitioners authorised by the competent administration.

The law identifies relevant professional qualifications, including specialists in obstetrics and gynaecology, medical biologists and pharmaceutical biologists.

3. Regulatory supervision

Article 10 addresses the granting and withdrawal of authorisations for establishments, centres and practitioners.

4. Institutional responsibility

Article 11 defines private assisted-reproduction centres by reference to their exclusive purpose of providing assisted reproductive services.

These requirements ensure that reproductive biotechnology is conducted within a controlled healthcare environment rather than through unregulated commercial laboratories.

Ma Loi+1

9. Informed consent and reproductive autonomy

Informed consent is a fundamental requirement under Moroccan reproductive biotechnology legislation.

Article 13 of Law No. 47-14 requires the free and informed consent of both spouses.

Consent must be:

Voluntary.

Informed.

Expressed in writing.

Obtained after adequate medical explanation.

Based on information provided in a language understood by the spouses.

Article 16 imposes additional obligations on practitioners.

Before commencing treatment, the practitioner must verify the spouses' identities, assess the medical justification for treatment, review previous treatments, explain the proposed procedure and obtain the required consent.

This is particularly important in cases involving IVF, embryo preservation and genetic diagnosis.

Example:

Suppose a fertility clinic proposes genetic screening before embryo transfer. The clinic must explain the medical purpose, the relevant risks and the available treatment information before obtaining the required consent.

If the clinic performs the procedure without complying with statutory consent requirements, it may face criminal and professional consequences.

Ma Loi+1

10. Confidentiality and protection of reproductive genetic information

Reproductive biotechnology centres collect information that can reveal extremely private aspects of a person's biological and family identity.

The legal framework therefore requires confidentiality and appropriate data security.

Under Article 3 of Law No. 47-14, assisted reproduction must respect human dignity, physical and psychological integrity, privacy and confidentiality.

Law No. 09-08 supplements these obligations.

Its practical application includes:

Protecting genetic testing results.

Restricting access to fertility records.

Preventing unauthorised disclosure of embryo information.

Protecting patients' medical identities.

Maintaining appropriate data security.

Complying with applicable CNDP formalities.

Article 24 of Law No. 09-08 specifically addresses security measures for sensitive and health-related information.

Article 26 also requires professional confidentiality.

Legal problem:

If a reproductive clinic discloses a patient's genetic disorder or infertility diagnosis without lawful justification, the disclosure may give rise to data-protection liability and other legal consequences.

BDJ+2

11. Inspection, regulatory accountability and criminal enforcement

Law No. 47-14 establishes a system of administrative inspection and criminal sanctions.

A. Advisory Commission

Article 31 establishes the Consultative Commission on Medically Assisted Reproduction.

Its role includes providing opinions on matters relating to assisted reproductive technologies and advising the competent administration.

Articles 32–34 address the appointment, independence, conflicts of interest and confidentiality obligations of commission members.

B. Inspection powers

Articles 35–38 establish inspection and enforcement mechanisms.

Authorised inspectors can:

Investigate suspected violations.

Inspect reproductive healthcare facilities.

Examine relevant medical and administrative records.

Conduct technical inspections.

Seize relevant documents and materials under the statutory safeguards.

Article 37 provides for technical inspections at least once annually.

C. Criminal penalties

The law establishes substantial penalties for violations.

Article 44 additionally permits professional prohibitions lasting five to ten years in cases covered by Articles 40 and 41.

Article 46 provides for doubling the applicable sanctions in cases of statutory recidivism.

Ma Loi+1

12. Important case laws and judicial precedents

An important research limitation must be recognised: publicly accessible Moroccan judgments specifically interpreting Law No. 47-14 after its enactment are difficult to identify. The following decisions and legal authorities should therefore be distinguished from direct judgments on assisted reproduction.

Case 1. Moroccan Court of Cassation, Decision No. 46 of 28 January 2009

Moroccan judicial precedent

Case reference:

Court: Moroccan Court of Cassation.

Decision: No. 46.

Date: 28 January 2009.

Case file: 232/2/1/2008.

Chamber: Personal Status and Succession.

Legal issue:

The dispute concerned the establishment of paternity where a husband alleged infertility and produced medical certificates supporting his claim.

Judicial principle:

The Court recognised the relevance of medical expertise in determining disputed paternity. The court should order medical expertise where the allegation of infertility is supported by medical evidence, and the resulting expert findings may assist in establishing biological parentage.

Relevance to reproductive biotechnology:

This decision is significant for reproductive health litigation because it illustrates the relationship between medical science, fertility evidence and legal parentage.

It is relevant to disputes involving:

Infertility diagnoses.

Genetic testing.

Biological parentage.

Medical evidence in family litigation.

The evidentiary value of reproductive medical records.

Critical analysis:

The decision predates Law No. 47-14 by approximately ten years. It must not be presented as a judgment interpreting that legislation. Its importance lies in the earlier judicial recognition of scientific and medical evidence in parentage disputes.

Jurisprudence+1

Case 2. Moroccan Family Code: Articles 152 and 153 — Judicial determination of paternity

Legal authority: Law No. 70-03, Moroccan Family Code.

These provisions are important judicial authorities rather than a separately identified reported judgment.

Article 152 establishes the recognised legal grounds for paternity.

Article 153 establishes the evidentiary importance of the marital relationship and provides a limited mechanism for challenging paternity through judicially ordered conclusive expertise.

Relevance to reproductive biotechnology:

Assisted reproduction creates questions about whether biological evidence and legally recognised parentage always correspond.

For example, where an IVF procedure uses the spouses' own reproductive material, the legal framework is designed to maintain consistency between the biological origins of the child and the legally recognised parental relationship.

The Family Code must therefore be interpreted alongside the specific restrictions contained in Law No. 47-14.

ويكي مصدر+1

Case 3. European Court of Human Rights, Evans v. United Kingdom (2007)

Comparative international authority

Citation: Evans v. United Kingdom, Application No. 6339/05, Grand Chamber judgment, 10 April 2007.

Legal issue:

The case concerned the use of embryos created through IVF and the withdrawal of one partner's consent to their continued use.

The European Court considered the relationship between reproductive autonomy, private life and the consent requirements governing assisted reproduction.

Judicial principle:

The Court examined the importance of consent in reproductive treatment and recognised that decisions concerning embryos involve competing personal interests.

Relevance to Morocco:

The case provides a useful comparative perspective on Article 13 of Moroccan Law No. 47-14.

It demonstrates why consent should be treated as an ongoing and legally significant aspect of reproductive treatment, rather than merely an administrative formality.

Important distinction: This is a European judgment, not binding Moroccan precedent.

Case 4. European Court of Human Rights, S.H. and Others v. Austria (2011)

Citation: S.H. and Others v. Austria, Application No. 57813/00, Grand Chamber judgment, 3 November 2011.

Legal issue:

The case concerned restrictions on certain assisted reproductive techniques, including donor sperm and egg donation.

Judicial principle:

The Grand Chamber considered reproductive autonomy under Article 8 of the European Convention on Human Rights and the state's discretion in regulating medically assisted reproduction.

Relevance to Morocco:

This case provides a comparative framework for analysing Morocco's restrictions on donor gametes under Article 5 and Article 12 of Law No. 47-14.

It illustrates the legal tension between individual reproductive choices, medical progress, family policy and the state's authority to regulate reproductive technologies.

Important distinction: The European Convention and this judgment do not automatically govern Morocco. The case is useful for comparative legal analysis only.

Case 5. European Court of Human Rights, Costa and Pavan v. Italy (2012)

Citation: Costa and Pavan v. Italy, Application No. 54270/10, judgment of 28 August 2012.

Legal issue:

The case concerned restrictions on preimplantation genetic diagnosis for a couple seeking to avoid transmitting a serious hereditary disease to their child.

Judicial principle:

The Court examined whether restrictions on access to reproductive genetic screening were compatible with the applicants' right to respect for private and family life.

Relevance to Morocco:

This judgment is particularly useful for evaluating Articles 19–21 of Law No. 47-14.

It raises important comparative questions concerning:

Genetic disease prevention.

Reproductive decision-making.

Access to preimplantation diagnosis.

Medical necessity.

The proportionality of restrictions on genetic screening.

Morocco's legislation permits certain forms of preimplantation diagnosis, but only within its prescribed statutory conditions.

Important distinction: This decision is persuasive comparative material, not binding Moroccan law.

13. Practical legal problems arising from reproductive biotechnology

Several difficult legal issues arise from the interaction between biotechnology, family law and healthcare regulation.

14. Cross-border reproductive biotechnology services

Cross-border reproductive treatment is an increasingly important issue.

Individuals may seek fertility treatment outside Morocco because certain technologies or reproductive arrangements are unavailable under domestic legislation.

However, international treatment does not automatically eliminate Moroccan legal restrictions.

Article 30 of Law No. 47-14 is particularly important because:

Exporting embryos, gametes and germinal tissues is prohibited.

Importing embryos is prohibited.

Importing gametes and germinal tissues requires special administrative authorisation.

The importation must meet applicable quality and traceability standards.

A further issue arises when a Moroccan citizen enters into a surrogacy agreement abroad.

The existence of a foreign agreement does not automatically establish that the arrangement will receive legal recognition in Morocco. Questions of parentage, public policy, family status and the circumstances of the child's birth require separate legal analysis.

Moroccan authorities and courts must therefore consider the applicable domestic rules rather than assuming that foreign reproductive arrangements are automatically enforceable.

Ma Loi+2

15. Constitutional and human-rights considerations

Reproductive health biotechnology must also be considered in the context of Morocco's constitutional protections.

Important constitutional principles include:

Article 19: Equality between women and men and the protection of their rights.

Article 20: The right to life.

Article 22: Protection of physical and moral integrity and prohibition of inhuman or degrading treatment.

Article 24: Protection of private life.

Article 31: State responsibility concerning access to healthcare and medical services.

These constitutional provisions provide a broader framework for evaluating reproductive healthcare regulation.

A significant legal question is whether restrictions on access to assisted reproductive services strike an appropriate balance between medical safety, family policy, personal autonomy and equality.

The constitutional framework should be read together with Law No. 47-14 rather than treated as an independent authorisation for reproductive procedures.

16. Critical evaluation of Morocco's regulatory framework

Morocco's reproductive biotechnology framework has several important strengths and challenges.

Strengths

A specific statute regulates medically assisted reproduction.

It establishes professional and institutional authorisation requirements.

It protects reproductive genetic information.

It requires informed written consent.

It restricts commercial exploitation of reproductive material.

It provides criminal penalties for serious violations.

It recognises genetic diagnosis for specified medical purposes.

Regulatory challenges

The restriction of treatment to married heterosexual couples limits access for other individuals.

The prohibition of gamete donation restricts certain fertility-treatment options.

The prohibition of surrogacy creates difficulties for individuals seeking alternative reproductive arrangements.

The restrictions on embryo research may limit certain areas of scientific investigation.

The preservation and destruction rules create difficult questions for patients undergoing prolonged medical treatment.

Cross-border reproductive services create conflicts between domestic law and foreign legal arrangements.

The development of newer technologies, including advanced embryo screening and genome editing, creates continuing questions about the scope of existing statutory restrictions.

An important distinction is that the legal permission to use one reproductive technology does not automatically authorise every new scientific application of that technology.

17. Suggestions for legal and regulatory reform

Several reforms could improve the effectiveness of Morocco's reproductive biotechnology framework.

First, clearer regulatory guidelines: The government could provide more detailed technical rules for fertility clinics, genetic laboratories and embryo-preservation facilities.

Second, stronger genetic privacy protection: Reproductive clinics should implement strict cybersecurity, access controls and confidentiality procedures.

Third, improved patient protection: Standardised consent documents and transparent explanations of treatment risks could improve patient decision-making.

Fourth, stronger regulatory monitoring: Regular inspections, professional audits and transparent reporting could strengthen accountability.

Fifth, scientific regulation: New reproductive technologies should be evaluated through transparent scientific, medical and ethical procedures before being authorised.

Sixth, judicial clarity: Published judicial decisions addressing parentage, embryo preservation, medical negligence and reproductive consent would improve legal certainty.

18. Conclusion

The regulation of reproductive health biotechnology services in Morocco is principally governed by Law No. 47-14 of 2019 on Medically Assisted Reproduction, supplemented by Law No. 131-13 on medical practice, Law No. 09-08 on personal data protection and the Moroccan Family Code.

The framework establishes strict requirements concerning eligibility, consent, medical licensing, IVF, genetic diagnosis, embryo preservation and reproductive material management.

It also expressly prohibits reproductive cloning, commercial exploitation of reproductive material, gamete donation and surrogacy.

The Moroccan Court of Cassation's Decision No. 46 of 28 January 2009 provides relevant historical jurisprudence concerning infertility evidence and biological parentage, while European human-rights decisions provide comparative perspectives on reproductive autonomy and genetic screening.

Ultimately, Morocco's regulatory approach seeks to reconcile medical innovation with human dignity, family law, genetic privacy, professional accountability and the protection of future children.

19. Important legal references and research sources

Primary research sources:

Law No. 47-14 – Full legislative text.

Moroccan Ministry of Health – Medical practice regulations.

Law No. 09-08 – Official legal database.

Moroccan CNDP – Data protection legislation.

Moroccan Court of Cassation – Decision No. 46 of 2009.

Moroccan Family Code – English translation.

Academic research note: The Moroccan Court of Cassation decision discussed above is an identifiable domestic precedent, but it predates Law No. 47-14. The European judgments are comparative authorities only. No directly reported Moroccan appellate judgment interpreting Law No. 47-14 has been verified in the sources consulted. This distinction is important when preparing a dissertation, journal article or legal case-law analysis.